Population Pharmacokinetics of Rituximab in Treatment‐Naïve Chinese Patients With Diffuse Large B‐cell Lymphoma During Induction Therapy: Clinical Implications
Clinical and Translational Science · 2026-08 · 19 (8)
DOI: 10.1111/cts.70683 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 25.07.2026. Verfasst von Wan-Yi Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Rituximab, Lymphoma, Large B-Cell, Diffuse, Models, Biological, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This study aimed to establish and validate a population pharmacokinetic model for rituximab during induction therapy in treatment‐naive patients with diffuse large B‐cell lymphoma, identify covariates affecting key pharmacokinetic parameters, and predict exposure. This retrospective study included newly diagnosed patients receiving rituximab‐containing induction regimens. Blood samples were collected before the next dose and after completion of the current dose across different chemotherapy cycles during the induction therapy; plasma concentrations were measured by chemiluminescent immunoassay. A nonlinear mixed‐effects model was developed and externally validated. Individual parameters were obtained using empirical Bayesian methods, and first‐cycle trough concentrations were predicted. For model building, 45 patients and 115 samples were included; external validation used 12 patients and 28 samples. Rituximab pharmacokinetics were described by a two‐compartment model. Representative estimates were: clearance 0.0181 L/h, central volume 8.12 L, intercompartmental clearance 0.0213 L/h, peripheral volume 29.2 L. Albumin‐globulin ratio was the final covariate and significantly affected clearance. Validation indicated good stability and predictive performance. Predicted first‐cycle trough concentrations were below the reference efficacy threshold, and lower troughs were associated with smaller albumin‐globulin ratios. This model quantified the effect of albumin‐globulin ratio on clearance and suggests a risk of insufficient rituximab exposure during induction therapy, supporting future individualized dosing and therapeutic drug monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
- College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China.
- Department of Pharmacy, The First people's Hospital of Changzhou, Changzhou, Jiangsu, China.
ORCID-Profile: Wan-Yi Zhou, Jing Ling, Meng-Meng Guan, Ying Qu, Ying-Hui Dan, Rong Chen
Zitieren
APA
Zhou, W. Y., Ling, J., Guan, M. M., Qu, Y., Dan, Y. H., & Chen, R. (2026). Population Pharmacokinetics of Rituximab in Treatment‐Naïve Chinese Patients With Diffuse Large B‐cell Lymphoma During Induction Therapy: Clinical Implications. Clinical and Translational Science, 19(8). https://doi.org/10.1111/cts.70683
Vancouver
Zhou WY, Ling J, Guan MM, Qu Y, Dan YH, Chen R. Population Pharmacokinetics of Rituximab in Treatment‐Naïve Chinese Patients With Diffuse Large B‐cell Lymphoma During Induction Therapy: Clinical Implications. Clinical and Translational Science. 2026;19(8). doi:10.1111/cts.70683
BibTeX
@article{Zhou2026,
author = {Zhou, Wan-Yi and Ling, Jing and Guan, Meng-Meng and Qu, Ying and Dan, Ying-Hui and Chen, Rong},
title = {Population Pharmacokinetics of Rituximab in Treatment‐Naïve Chinese Patients With Diffuse Large B‐cell Lymphoma During Induction Therapy: Clinical Implications},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {8},
doi = {10.1111/cts.70683}
}
EUVIMED